Skip to main content
. 2021 Nov 24;81(3):359–369. doi: 10.1136/annrheumdis-2021-220991

Figure 3.

Figure 3

ACR20 response at week 24 by baseline characteristics of COSMOS participants. ACR20, ≥20% improvement in American College of Rheumatology response criteria; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; GUS, guselkumab; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo; Q8W, every 8 weeks; TNFi, tumour necrosis factor inhibitor.